ClinicalTrials.gg
CompletedNCT07101731Updated Oct 5, 2026

Effects of Hypopressive Exercises on Urinary Incontinence and Erectile Dysfunction After Radical Prostatectomy

An interventional study of Pelvic Floor Muscle Training (PFMT) and Hypopressive Exercises in Prostate Cancer (Post Prostatectomy), Urinary Incontinence and Erectile Dysfunction Following Radical Prostatectomy, sponsored by Bartın Unıversity. Completed at 1 site in Turkey (Türkiye). Open to male participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Bartın Unıversity · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Jun 2024, registered Jul 2025).
Updated Oct 5, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
55 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 111 studies in Prostatic Neoplasms with a site in Turkey — 22 open to participants now, 42 under way, 21 of them phase 3. Prostatic Neoplasms · Turkey.

Enrollment
87th of 90
30 · median 226
Started
2024
with 9 others
No phase
40 of 111
6 open now
Registered
87th of 111
by date

Among the 111 studies in Prostatic Neoplasms with a site in Turkey, this one is the 87th largest by enrollment of the 90 interventional ones that give a count, is one of 10 that started in 2024, is one of 40 with no phase, and was the 87th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

22 of the 111 studies in Prostatic Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 55 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Prostatic Neoplasms with a site in Turkey, or all of them as a file.
02

Study summary

This randomized controlled trial investigates the effects of hypopressive exercises on urinary incontinence and erectile dysfunction in men following radical prostatectomy. Participants will be randomly assigned to one of two groups: a control group receiving home-based pelvic floor muscle exercises and an experimental group receiving both pelvic floor muscle exercises and supervised hypopressive exercises twice per week. The study aims to determine whether the addition of hypopressive techniques, which target coordinated activation of the pelvic floor and abdominal muscles without increasing intra-abdominal pressure, offers greater improvements in urinary and sexual function. Primary outcomes include pelvic floor muscle strength and endurance, while secondary outcomes include urinary incontinence severity, erectile function, and quality of life.

Read the detailed description

Prostate cancer is one of the most common malignancies among men, with radical prostatectomy being a widely used treatment option. However, post-surgical complications such as urinary incontinence and erectile dysfunction significantly affect the quality of life of these patients. Pelvic floor muscle training (PFMT) is frequently recommended to manage these complications, yet its standalone effectiveness remains debatable.

Recent literature highlights that optimal pelvic floor function is achieved through coordinated activation with abdominal and respiratory muscles, such as the transversus abdominis, rectus abdominis, and diaphragm. Despite this, conventional PFMT protocols for post-prostatectomy patients often neglect this integrated muscle synergy. Hypopressive exercises, which involve postural techniques with apnea and breathing control, have been shown to activate both pelvic floor and abdominal muscles without increasing intra-abdominal pressure.

This study aims to evaluate the effects of hypopressive exercises, in addition to standard pelvic floor exercises, on pelvic floor muscle strength, urinary incontinence severity, and erectile function in post-prostatectomy men. The study will be conducted with two arms: a control group performing home-based pelvic floor exercises and an experimental group performing the same PFMT along with supervised hypopressive exercises twice weekly for 8 weeks. Outcomes will be assessed pre- and post-intervention, focusing on both physical performance and patient-reported measures.

03

Conditions studied

  • Prostate Cancer (Post Prostatectomy)
  • Urinary Incontinence
  • Erectile Dysfunction Following Radical Prostatectomy
  • Pelvic Floor Muscle Training

Keywords

  • Radical Prostatectomy
  • Urinary Incontinence
  • Erectile Dysfunction
  • Pelvic Floor Muscle Training
  • Hypopressive Exercises
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male individuals diagnosed with prostate cancer who have undergone radical prostatectomy
  • Experiencing both urinary incontinence and erectile dysfunction
  • Age > 55 years
  • A score of 24 or higher on the (MMSE)
  • Literate (able to read and write)
  • Willingness to participate in the study (signed )
  • Ability to voluntarily contract pelvic floor muscles
  • Ability to cooperate with the assessments and interventions used in the study

Exclusion criteria

Exclusion Criteria

  • History of urinary incontinence before surgery
  • Congenital abnormalities of the urinary system
  • Presence of neurological disorders
  • History of transurethral resection of the prostate (TURP)
  • Diagnosis of (COPD) and/or chronic restrictive pulmonary disease
  • History of inguinal hernia
  • Previous or current history of radiation therapy
  • Surgical or postoperative complications that prevent early physiotherapy intervention (e.g., urinary tract infection, bladder neck stenosis)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Pelvic Floor Home Exercise + Supervised Hypopressive Exercise Group

    Participants will perform daily home-based pelvic floor muscle exercises and also attend supervised hypopressive exercise sessions twice a week for 8 weeks.

    Behavioral: Pelvic Floor Muscle Training (PFMT) · Behavioral: Hypopressive Exercises

  • Active comparator
    Pelvic Floor Home Exercise Only Group

    Participants will be instructed to perform home-based pelvic floor muscle exercises daily for 8 weeks. No supervised exercise sessions will be provided.

    Behavioral: Pelvic Floor Muscle Training (PFMT)

Interventions

  • BehavioralPelvic Floor Muscle Training (PFMT)

    Participants in the control group will receive an individualized home-based pelvic floor muscle exercise program. Exercises will be performed once daily for 8 weeks, focusing on voluntary pelvic floor contractions in various positions (supine, sitting, standing). Participants will receive initial training and written instructions from a physiotherapist, and will be contacted weekly to monitor adherence.

  • BehavioralHypopressive Exercises

    Participants in the experimental group will attend supervised hypopressive exercise sessions twice per week for 8 weeks. These sessions involve specific postural sequences combined with breathing and apnea techniques aimed at reducing intra-abdominal pressure while activating pelvic floor and abdominal muscles. Sessions will be led by a physiotherapist and adapted based on individual performance and posture tolerance.

06

What researchers measure

Primary outcomes

  1. Change in ICIQ-SF Total Score

    The International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF) will be used to assess perceived severity and quality of life impact of urinary incontinence. The total score is based on responses to questions 3, 4, and 5 (range: 0-21). Higher scores indicate more severe incontinence.

    Time frame: Baseline and 8 weeks

Secondary outcomes

  1. Change in erectile function measured by IIEF-5

    Erectile function will be assessed using the 5-item version of the International Index of Erectile Function (IIEF-5). Total scores range from 5 to 25, with lower scores indicating more severe erectile dysfunction. The change in total score from baseline to post-intervention will be analyzed.

    Time frame: Baseline and 8 weeks

  2. Change in pelvic floor muscle strength measured by Modified Oxford Scale

    Pelvic floor muscle strength will be assessed by manual digital palpation in a side-lying position with knees flexed at 45 degrees. Strength will be scored using the Modified Oxford Scale, which ranges from 0 (no contraction) to 5 (strong contraction). Higher scores indicate better pelvic floor muscle strength.

    Time frame: Baseline and 8 weeks

  3. Change in urinary incontinence severity measured by 1-hour Pad Test

    The 1-hour Pad Test, standardized by the International Continence Society (ICS), will be used to objectively assess urinary leakage. A weight gain of \>1g indicates a positive test. Severity will be classified as mild (\<2g), moderate (2-10g), severe (10-50g), or very severe (\>50g). The difference in pad weight pre- and post-intervention will be recorded.

    Time frame: Baseline and 8 weeks

  4. Change in quality of life measured by King's Health Questionnaire

    The King's Health Questionnaire will be used to assess health-related quality of life in individuals with urinary incontinence. The questionnaire includes multiple subdomains, with scores ranging from 0 (best health status) to 100 (worst). A decrease in score indicates improvement.

    Time frame: Baseline and 8 weeks

  5. Adherence to the Exercise Programme

    Adherence to the home-based pelvic floor muscle training programme was assessed in both groups using participant exercise diaries. Adherence was calculated as the percentage of prescribed home-based PFMT sets completed during the eight-week intervention. Higher percentages indicate greater adherence to the prescribed home-based PFMT programme.

    Time frame: Throughout the 8-week intervention

  6. Treatment Success

    Treatment success was defined as a reduction of at least 50% in the 1-hour pad-test value from baseline to Week 8. Participants were classified as responders or non-responders.

    Time frame: Week 8 compared with baseline

07

Study locations

1 site
  • University of Health Sciences, Gülhane Training and Research Hospital
    Ankara, Ankara 06010, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Undecided — The individual participant data (IPD) sharing decision has not been finalized. Although publication of the study results is planned, the possibility of sharing de-identified IPD with other researchers will depend on institutional policies, ethical approvals, and publication guidelines.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Dec 2025, 18 months.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's 18 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Nov 2025 → Dec 2025 and completion Nov 2025 → Dec 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2025
First posted
Aug 3, 2025
StartActual
Jun 1, 2024
Primary completionActual
Dec 15, 2025was Nov 2025
CompletionActual
Dec 15, 2025was Nov 2025
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 5, 2026
Primary completion
Nov 15, 2025→Dec 15, 2025 (actual)
Oct 5, 2026
Study completion
Nov 15, 2025→Dec 15, 2025 (actual)
Oct 5, 2026
Primary outcomes
1 added, 3 removed
What changed in the outcomes
  • AddedChange in ICIQ-SF Total ScoreTime frame: Baseline and 8 weeks
  • RemovedChange in urinary incontinence severity measured by 1-hour Pad TestTime frame: Baseline and 8 weeks
  • RemovedChange in pelvic floor muscle strength measured by Modified Oxford ScaleTime frame: Baseline and 8 weeks
  • RemovedChange in pelvic floor muscle endurance measured in secondsTime frame: Baseline and Week 8
Oct 5, 2026
Secondary outcomes
1 edited, 3 added, 3 removed
What changed in the outcomes
  • EditedChange in urinary incontinence severity and impact measured by ICIQ1-SFhour Pad TestTime frame: Baseline and 8 weeks
  • AddedChange in pelvic floor muscle strength measured by Modified Oxford ScaleTime frame: Baseline and 8 weeks
  • AddedAdherence to the Exercise ProgrammeTime frame: Throughout the 8-week intervention
  • AddedTreatment SuccessTime frame: Week 8 compared with baseline
  • RemovedChange in urinary frequency and incontinence episodes measured by 3-day bladder diaryTime frame: Baseline and 8 weeks
  • RemovedChange in perceived urinary symptom severity measured by Patient Global Impression of Severity (PGI-S)Time frame: Baseline and 8 weeks
  • RemovedPerceived improvement in urinary symptoms measured by Patient Global Impression of Improvement (PGI-I)Time frame: Week 8
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Recruiting→Completed
    Primary completion Nov 15, 2025→Dec 15, 2025 (now actual)
    Study completion Nov 15, 2025→Dec 15, 2025 (now actual)
    Primary outcomes 1 added, 3 removed
    What changed in the outcomes
    • AddedChange in ICIQ-SF Total ScoreTime frame: Baseline and 8 weeks
    • RemovedChange in urinary incontinence severity measured by 1-hour Pad TestTime frame: Baseline and 8 weeks
    • RemovedChange in pelvic floor muscle strength measured by Modified Oxford ScaleTime frame: Baseline and 8 weeks
    • RemovedChange in pelvic floor muscle endurance measured in secondsTime frame: Baseline and Week 8
    Secondary outcomes 1 edited, 3 added, 3 removed
    What changed in the outcomes
    • EditedChange in urinary incontinence severity and impact measured by ICIQ1-SFhour Pad TestTime frame: Baseline and 8 weeks
    • AddedChange in pelvic floor muscle strength measured by Modified Oxford ScaleTime frame: Baseline and 8 weeks
    • AddedAdherence to the Exercise ProgrammeTime frame: Throughout the 8-week intervention
    • AddedTreatment SuccessTime frame: Week 8 compared with baseline
    • RemovedChange in urinary frequency and incontinence episodes measured by 3-day bladder diaryTime frame: Baseline and 8 weeks
    • RemovedChange in perceived urinary symptom severity measured by Patient Global Impression of Severity (PGI-S)Time frame: Baseline and 8 weeks
    • RemovedPerceived improvement in urinary symptoms measured by Patient Global Impression of Improvement (PGI-I)Time frame: Week 8
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07101731
Lead sponsor
Bartın Unıversity
Responsible party
Betül ERBAY (Lecturer, Bartın Unıversity) — Principal investigator
First posted
Aug 3, 2025
Start date
Jun 1, 2024
Primary completion
Dec 15, 2025
Completion
Dec 15, 2025
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion